Developer docs
API playgroundTry for free, no card

Search company profiles

Unither Pharmaceuticals

Full company profile

uuid0008ofn

Namestring
Unither Pharmaceuticals
Legal namestring
UNITHER PHARMACEUTICALS SAS
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Unither Pharmaceuticals is a privately held French Contract Development and Manufacturing Organization (CDMO) founded in 1993 and headquartered in Paris. The company specializes in sterile and non-sterile liquid pharmaceutical forms, including single-dose, multi-dose, vials, liquid stick-packs, and sprays, and is self-identified as the world leader in Blow-Fill-Seal (BFS) technology, with an annual production capacity exceeding 5 billion doses across 9 production sites on four continents (France, United States, Brazil, China) and approximately 2,490 employees as of December 2025. Products are distributed to more than 100 countries.

Its core technology platform is BFS, a continuous aseptic process that combines polymer extrusion, container forming, filling, and sealing in a single automated operation under sterile air shower, producing sterile-by-construction unit-dose containers. The portfolio of proprietary platforms extends BFS into adjacent delivery formats: Euroject (BFS-based injectable for biologics), Sol-Gel (ophthalmic sustained-delivery gels), Uniflash (oro-mucosal delivery), and Carragelose (a CE-certified carrageenan-based nasal/ophthalmic antiviral platform acquired from Marinomed Biotech in November 2024 for up to EUR 20 million). Multi-dose containers with preservative or preservative-free formats, nasal/respiratory sprays, and pediatric-oriented liquid stick-packs round out the technology set.

Unither generates revenue through three principal streams: (1) CDMO contract manufacturing services spanning technology transfer, scale-up, clinical and commercial batch production for pharmaceutical clients; (2) co-development partnerships in which Unither collaborates with clients to design and industrialize new products; and (3) out-licensing of turnkey products and ready-to-register dossiers, including Carragelose, Euroject, Sol-Gel, and Uniflash, to pharmaceutical clients for marketing under their own brands. The company serves customers from start-ups to large international pharmaceutical firms across therapeutic areas including ophthalmology, ENT, injectable, respiratory, and rare diseases. Pricing is project-specific and quote-based. Recent strategic actions include the groundbreaking of a new industrial facility in Gannat, France (January 2026), the Carragelose acquisition (2024), the SeaBeLife joint development agreement for SBL03 in retinal disease (2025), and the appointment of Henrik Krüpper as CEO.

Short descriptiontext

Unither Pharmaceuticals is a French CDMO and world leader in Blow-Fill-Seal (BFS) sterile liquid manufacturing, operating 9 production sites across 4 continents with 5+ billion annual doses capacity, serving pharmaceutical companies from startups to large international firms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, blow-fill-seal technology, sterile liquid dosage forms, CDMO development services, ophthalmic drug formulations
Industry3 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Manufacturing Services
TypeProfessional Services
Description

CDMO manufacturing services for clinical and commercial batches. Unither produces sterile and non-sterile liquid pharmaceuticals, BFS unit-doses, multi-dose containers, sprays, stick-packs, and vials for pharmaceutical clients from preclinical phases through commercial scale.

unither-pharma.com
2Co-Development Partnerships
TypeProfessional Services
Description

Collaborative product development model where Unither works closely with clients to design, develop, and industrialize new products, reducing time-to-market for innovative health solutions.

unither-pharma.com
3Out-Licensing
TypeLicensing Royalties
Description

Turnkey product solutions including ready-to-register product dossiers and licensed medical devices and drugs. Includes products like Carragelose, Euroject, Sol-Gel, and Uniflash offered for licensing to clients who can market under their own brand.

unither-pharma.com
4Product Acquisition
TypeOne Time License
Description

Acquisition of product lines and businesses such as the Carragelose business from Marinomed Biotech AG for up to EUR 20 million, expanding Unither's product portfolio and market presence.

pharmiweb.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Euroject®
Description

BFS-based injectable drug delivery device for unit-dose injection of biologics

unither-pharma.com
+5 more records
Core offering1 text field

Unither Pharmaceuticals is a French Contract Development and Manufacturing Organization (CDMO) that develops, formulates, and manufactures sterile and non-sterile liquid pharmaceutical dosage forms for other pharmaceutical companies. It is the world leader in Blow-Fill-Seal (BFS) technology for sterile single-dose manufacturing, with an annual production capacity exceeding 5 billion doses, and also offers multi-dose, spray, stick-pack, vial, and injectable formats alongside proprietary platforms such as Euroject, Carragelose, Sol-Gel, and Uniflash.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Annual production capacity exceeding 5 billion doses using BFS technology
+3 more records
Product overview1 text field

Unither Pharmaceuticals is a Contract Development and Manufacturing Organization (CDMO) specializing in sterile and non-sterile liquid pharmaceutical forms. The company's core technology is Blow-Fill-Seal (BFS), the world's leading BFS platform with 5 billion annual dose capacity. Their product portfolio includes BFS single doses, multi-dose containers, sprays, liquid stick-packs, and vials. Breakthrough solutions include Euroject (BFS injectable), Carragelose (viral protection), Sol-Gel (ophthalmology), and Uniflash (oro-mucosal). Services span manufacturing (technology transfer, scale-up, commercial batches, rare disease and veterinary), development (formulation, analytical, clinical, stability, regulatory), and out-licensing of turnkey products. Therapeutic applications focus on ophthalmology, ENT, injectable, respiratory, and rare diseases.

Product and service1 record
1Pharmaceutical Manufacturing Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Collaborative research partnership with Unither Développement Bordeaux on scientific publications regarding ophthalmology, including research on polyunsaturated fatty acids and age-related macular degeneration published in the International Journal of Molecular Sciences.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-22
Description

Collaboration on 'Eye to Market' web series exploring how ophthalmic innovations move from scientific development to real-world patient adoption. Series features expert interviews on translational research, clinical development, manufacturing, regulatory strategy, and market access. Published on Eyecelerator YouTube channel targeting innovators, clinicians, investors, and industry leaders.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Joint development agreement for SBL03, a topical ophthalmic drug candidate for treating degenerative retinal disorders such as geographic atrophy and dry age-related macular degeneration. Unither handles pharmaceutical development, industrial scale-up, and GMP batch manufacturing. Clinical trials planned for 2027. SeaBeLife retains ownership of the drug candidate while Unither provides manufacturing expertise.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-26
Description

Acquisition of Marinomed's Carragelose business for up to EUR 20 million based on target achievement. Carragelose is a viral infection protection platform based on carrageenan technology. Proceeds fund Marinomed's restructuring and growth in its Marinosolv platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Catalent is one of the largest global CDMOs with a broad service portfolio spanning oral, injectable, and biologic drug delivery. Comparable to Unither as a direct CDMO competitor for sterile fill-finish and injectable manufacturing, though at a much larger scale and broader therapeutic reach.

TypeBroad incumbent
Description

Lonza is the world's largest CDMO by revenue, offering mammalian and microbial biologics manufacturing as well as fill-finish services. Directly comparable to Unither in sterile injectable and biologic fill-finish, with substantially larger scale and a broader technology portfolio.

3Recipharm
TypeDirect peer
Description

Recipharm is a European-headquartered CDMO focused on sterile fill-finish, inhalation, and biologics. Comparable to Unither in providing B2B contract sterile manufacturing to pharma companies, with similar geographic reach across Europe and overlapping capabilities in ophthalmic and injectable CDMO services.

4Fareva
TypeDirect peer
Description

Fareva is a French-headquartered CDMO with sterile injectable, ophthalmic, and topical manufacturing capabilities. Highly comparable to Unither as a fellow French sterile and ophthalmic CDMO serving multinational pharma clients with similar CDMO service offerings.

TypeDirect peer
Description

Delpharm is a leading French CDMO offering sterile and non-sterile manufacturing services to pharma companies across Europe. Directly comparable to Unither as a French-headquartered contract manufacturer serving multinational pharma with liquid and sterile dosage form capabilities.

TypeDirect peer
Description

Aenova is a European CDMO providing sterile and non-sterile manufacturing including softgel capsules, sterile liquids, and injectables. Comparable to Unither as a European-based contract manufacturer with overlapping capabilities in sterile liquid pharmaceutical manufacturing for global pharma clients.

TypeDirect peer
Description

Rommelag is a German specialist in Blow-Fill-Seal (BFS) aseptic packaging technology for pharmaceuticals. The closest direct peer to Unither in BFS technology, also serving pharma clients with aseptic unit-dose manufacturing; together they constitute the leading global BFS CDMO duopoly.

TypeEmerging player
Description

Stevanato Group is an Italian manufacturer of glass primary packaging and integrated fill-finish solutions for injectable drugs. Comparable to Unither in sterile injectable manufacturing services, with growing pharma services offerings adjacent to Unither's Euroject BFS injectable platform.

TypeBroad incumbent
Description

BD Medical Pharmaceutical Systems is a global manufacturer of prefilled syringes, auto-injectors, and BFS-based delivery systems for injectables. Comparable to Unither as a competing supplier of sterile unit-dose and injectable delivery platforms, though BD focuses on device manufacturing rather than CDMO services.

TypeDirect peer
Description

Kindeva Drug Delivery is a global CDMO specializing in inhalation, injectable, and transdermal drug delivery, with BFS and aseptic fill-finish capabilities. Directly comparable to Unither as a CDMO serving pharma clients with sterile unit-dose and injectable manufacturing across multiple sites.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance14 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Unither Pharmaceuticals

Pharmaceutical Contract Manufacturingunither-pharma.com

Unither Pharmaceuticals is a French CDMO and world leader in Blow-Fill-Seal (BFS) sterile liquid manufacturing, operating 9 production sites across 4 continents with 5+ billion annual doses capacity, serving pharmaceutical companies from startups to large international firms.

What Unither Pharmaceuticals does

Unither Pharmaceuticals is a privately held French Contract Development and Manufacturing Organization (CDMO) founded in 1993 and headquartered in Paris. The company specializes in sterile and non-sterile liquid pharmaceutical forms, including single-dose, multi-dose, vials, liquid stick-packs, and sprays, and is self-identified as the world leader in Blow-Fill-Seal (BFS) technology, with an annual production capacity exceeding 5 billion doses across 9 production sites on four continents (France, United States, Brazil, China) and approximately 2,490 employees as of December 2025. Products are distributed to more than 100 countries.

Its core technology platform is BFS, a continuous aseptic process that combines polymer extrusion, container forming, filling, and sealing in a single automated operation under sterile air shower, producing sterile-by-construction unit-dose containers. The portfolio of proprietary platforms extends BFS into adjacent delivery formats: Euroject (BFS-based injectable for biologics), Sol-Gel (ophthalmic sustained-delivery gels), Uniflash (oro-mucosal delivery), and Carragelose (a CE-certified carrageenan-based nasal/ophthalmic antiviral platform acquired from Marinomed Biotech in November 2024 for up to EUR 20 million). Multi-dose containers with preservative or preservative-free formats, nasal/respiratory sprays, and pediatric-oriented liquid stick-packs round out the technology set.

Unither generates revenue through three principal streams: (1) CDMO contract manufacturing services spanning technology transfer, scale-up, clinical and commercial batch production for pharmaceutical clients; (2) co-development partnerships in which Unither collaborates with clients to design and industrialize new products; and (3) out-licensing of turnkey products and ready-to-register dossiers, including Carragelose, Euroject, Sol-Gel, and Uniflash, to pharmaceutical clients for marketing under their own brands. The company serves customers from start-ups to large international pharmaceutical firms across therapeutic areas including ophthalmology, ENT, injectable, respiratory, and rare diseases. Pricing is project-specific and quote-based. Recent strategic actions include the groundbreaking of a new industrial facility in Gannat, France (January 2026), the Carragelose acquisition (2024), the SeaBeLife joint development agreement for SBL03 in retinal disease (2025), and the appointment of Henrik Krüpper as CEO.

Unither Pharmaceuticals firmographics

Firmographics
Name
Unither Pharmaceuticals
Legal name
UNITHER PHARMACEUTICALS SAS
Website
https://unither-pharma.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Unither Pharmaceuticals is a French CDMO and world leader in Blow-Fill-Seal (BFS) sterile liquid manufacturing, operating 9 production sites across 4 continents with 5+ billion annual doses capacity, serving pharmaceutical companies from startups to large international firms.
Ownership category
akta.pro rank

Unither Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Blow-fill-seal technology
  • Sterile liquid dosage forms
  • CDMO development services
  • Ophthalmic drug formulations

Where Unither Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices10 records

Markets served

Unither Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: CDMO manufacturing services for clinical and commercial batches. Unither produces sterile and non-sterile liquid pharmaceuticals, BFS unit-doses, multi-dose containers, sprays, stick-packs, and vials for pharmaceutical clients from preclinical phases through commercial scale.
  2. Co-Development Partnerships: Collaborative product development model where Unither works closely with clients to design, develop, and industrialize new products, reducing time-to-market for innovative health solutions.
  3. Out-Licensing: Turnkey product solutions including ready-to-register product dossiers and licensed medical devices and drugs. Includes products like Carragelose, Euroject, Sol-Gel, and Uniflash offered for licensing to clients who can market under their own brand.
  4. Product Acquisition: Acquisition of product lines and businesses such as the Carragelose business from Marinomed Biotech AG for up to EUR 20 million, expanding Unither's product portfolio and market presence.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Unither Pharmaceuticals product offering

Product offering

Core offering

Unither Pharmaceuticals is a French Contract Development and Manufacturing Organization (CDMO) that develops, formulates, and manufactures sterile and non-sterile liquid pharmaceutical dosage forms for other pharmaceutical companies. It is the world leader in Blow-Fill-Seal (BFS) technology for sterile single-dose manufacturing, with an annual production capacity exceeding 5 billion doses, and also offers multi-dose, spray, stick-pack, vial, and injectable formats alongside proprietary platforms such as Euroject, Carragelose, Sol-Gel, and Uniflash.

Product overview

Unither Pharmaceuticals is a Contract Development and Manufacturing Organization (CDMO) specializing in sterile and non-sterile liquid pharmaceutical forms. The company's core technology is Blow-Fill-Seal (BFS), the world's leading BFS platform with 5 billion annual dose capacity. Their product portfolio includes BFS single doses, multi-dose containers, sprays, liquid stick-packs, and vials. Breakthrough solutions include Euroject (BFS injectable), Carragelose (viral protection), Sol-Gel (ophthalmology), and Uniflash (oro-mucosal). Services span manufacturing (technology transfer, scale-up, commercial batches, rare disease and veterinary), development (formulation, analytical, clinical, stability, regulatory), and out-licensing of turnkey products. Therapeutic applications focus on ophthalmology, ENT, injectable, respiratory, and rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • Euroject®: BFS-based injectable drug delivery device for unit-dose injection of biologics
  • Carragelose®
  • Sol-Gel™
  • Uniflash®
  • InnoSphère
  • Inspire Hub

Products and services

  • Pharmaceutical Manufacturing Services

Quantifiable outcome

  • Annual production capacity exceeding 5 billion doses using BFS technology
  • +3 more outcomes

Companies that use Unither Pharmaceuticals

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Unither Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Unither Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Université Paris Cité, CNRS, INSERM, and other academic institutionsminorStrategic or Co-development Partner · 30 April 2026Collaborative research partnership with Unither Développement Bordeaux on scientific publications regarding ophthalmology, including research on polyunsaturated fatty acids and age-related macular degeneration published in the International Journal of Molecular Sciences.
  • Eyecelerator and Ora, Inc.minorGTM or Marketing Partner · 22 April 2026Collaboration on 'Eye to Market' web series exploring how ophthalmic innovations move from scientific development to real-world patient adoption. Series features expert interviews on translational research, clinical development, manufacturing, regulatory strategy, and market access. Published on Eyecelerator YouTube channel targeting innovators, clinicians, investors, and industry leaders.
  • SeaBeLifecoreStrategic or Co-development Partner · 9 December 2025Joint development agreement for SBL03, a topical ophthalmic drug candidate for treating degenerative retinal disorders such as geographic atrophy and dry age-related macular degeneration. Unither handles pharmaceutical development, industrial scale-up, and GMP batch manufacturing. Clinical trials planned for 2027. SeaBeLife retains ownership of the drug candidate while Unither provides manufacturing expertise.
  • Marinomed Biotech AGcoreOEM/ Whitelabel/ Licensing Partner · 26 November 2024Acquisition of Marinomed's Carragelose business for up to EUR 20 million based on target achievement. Carragelose is a viral infection protection platform based on carrageenan technology. Proceeds fund Marinomed's restructuring and growth in its Marinosolv platform.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Unither Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Catalent is one of the largest global CDMOs with a broad service portfolio spanning oral, injectable, and biologic drug delivery. Comparable to Unither as a direct CDMO competitor for sterile fill-finish and injectable manufacturing, though at a much larger scale and broader therapeutic reach.
  • Lonza Group: Lonza is the world's largest CDMO by revenue, offering mammalian and microbial biologics manufacturing as well as fill-finish services. Directly comparable to Unither in sterile injectable and biologic fill-finish, with substantially larger scale and a broader technology portfolio.
  • Becton, Dickinson and Company (BD): BD Medical Pharmaceutical Systems is a global manufacturer of prefilled syringes, auto-injectors, and BFS-based delivery systems for injectables. Comparable to Unither as a competing supplier of sterile unit-dose and injectable delivery platforms, though BD focuses on device manufacturing rather than CDMO services.

Direct peers

  • Recipharm: Recipharm is a European-headquartered CDMO focused on sterile fill-finish, inhalation, and biologics. Comparable to Unither in providing B2B contract sterile manufacturing to pharma companies, with similar geographic reach across Europe and overlapping capabilities in ophthalmic and injectable CDMO services.
  • Fareva: Fareva is a French-headquartered CDMO with sterile injectable, ophthalmic, and topical manufacturing capabilities. Highly comparable to Unither as a fellow French sterile and ophthalmic CDMO serving multinational pharma clients with similar CDMO service offerings.
  • Delpharm: Delpharm is a leading French CDMO offering sterile and non-sterile manufacturing services to pharma companies across Europe. Directly comparable to Unither as a French-headquartered contract manufacturer serving multinational pharma with liquid and sterile dosage form capabilities.
  • Aenova Group: Aenova is a European CDMO providing sterile and non-sterile manufacturing including softgel capsules, sterile liquids, and injectables. Comparable to Unither as a European-based contract manufacturer with overlapping capabilities in sterile liquid pharmaceutical manufacturing for global pharma clients.
  • Rommelag: Rommelag is a German specialist in Blow-Fill-Seal (BFS) aseptic packaging technology for pharmaceuticals. The closest direct peer to Unither in BFS technology, also serving pharma clients with aseptic unit-dose manufacturing; together they constitute the leading global BFS CDMO duopoly.
  • Kindeva Drug Delivery: Kindeva Drug Delivery is a global CDMO specializing in inhalation, injectable, and transdermal drug delivery, with BFS and aseptic fill-finish capabilities. Directly comparable to Unither as a CDMO serving pharma clients with sterile unit-dose and injectable manufacturing across multiple sites.

Emerging players

  • Stevanato Group: Stevanato Group is an Italian manufacturer of glass primary packaging and integrated fill-finish solutions for injectable drugs. Comparable to Unither in sterile injectable manufacturing services, with growing pharma services offerings adjacent to Unither's Euroject BFS injectable platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Unither Pharmaceuticals social profiles

Digital presence

Unither Pharmaceuticals compliance and trust

Trust signal

Compliance14 records

Unither Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Unither Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

Unither Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Unither Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Unither Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unither Pharmaceuticals

What does Unither Pharmaceuticals do?

Unither Pharmaceuticals is a French Contract Development and Manufacturing Organization (CDMO) that develops, formulates, and manufactures sterile and non-sterile liquid pharmaceutical dosage forms for other pharmaceutical companies. It is the world leader in Blow-Fill-Seal (BFS) technology for sterile single-dose manufacturing, with an annual production capacity exceeding 5 billion doses, and also offers multi-dose, spray, stick-pack, vial, and injectable formats alongside proprietary platforms such as Euroject, Carragelose, Sol-Gel, and Uniflash.

Is Unither Pharmaceuticals a public or private company?

Unither Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.

When was Unither Pharmaceuticals founded?

Unither Pharmaceuticals was founded in 1993. It employs 1,001 to 5,000 people.

Where is Unither Pharmaceuticals based?

Unither Pharmaceuticals is headquartered in Paris, France, in the Europe region.

How does Unither Pharmaceuticals make money?

Four revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are co-Development Partnerships, out-Licensing and product Acquisition.

Who are Unither Pharmaceuticals's main competitors?

Broad incumbents on record are Catalent, Lonza Group and Becton, Dickinson and Company (BD). Direct peers are Recipharm, Fareva, Delpharm, Aenova Group, Rommelag and Kindeva Drug Delivery. Stevanato Group is listed as an emerging player.

Does Unither Pharmaceuticals have an API?

No public API is recorded for Unither Pharmaceuticals.

What industry is Unither Pharmaceuticals in?

Unither Pharmaceuticals's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deOriginal-Research: Marinomed Biotech AG (von GBC AG): Under ReviewThe Landesgericht Korneuburg opened a restructuring procedure without self-administration over Marinomed Biotech AG on July 23, 2026, following the breakdown of negotiations with Unither Pharmaceuticals and the non-payment of earn-out obligations from the February 2025 sale of the Carragelose business. The company faces liabilities of approximately €27.90 million and proposes a new restructuring quota of 20%, down from the original 30% plan, while the outcome hinges significantly on legal claims against Unither over allegedly missed targets. GBC AG has placed its BUY rating and €51.00 price target under review pending clarity on Unither claims, creditor approval, and financing of the new restructuring plan.24PresseThéa and Unither Pharmaceuticals Announce Industrial Partnership for a New Ophthalmic Manufacturing Facility in AuvergneThéa and Unither Pharmaceuticals have announced a strategic industrial partnership to construct a new manufacturing facility in Gannat, France, dedicated to producing Théa's sterile ophthalmic products. The project involves an investment of over €140 million, with operations scheduled to begin in 2028 and capacity for more than 50 million treatments annually. This exclusive arrangement aims to support Théa's growth across Europe while creating approximately 250 jobs by 2030.The Pharma LetterThéa and Unither partner on 140 million euros ophthalmic manufacturing facilityFrench ophthalmology specialist Théa has entered into a long-term manufacturing partnership with French CDMO Unither Pharmaceuticals to build a dedicated sterile eye care production facility at Unither's Gannat site in central France. The project represents an investment of more than 140 million euros and will be primarily dedicated to producing Théa's sterile ophthalmic products. The 20,000-square-meter plant is expected to strengthen manufacturing capacity for Théa's ophthalmic portfolio under a multi-year agreement.AInvestMarinomed Biotech AG - company to utilize legal options against Unither over Carragelose and Marinosolv assetsMarinomed Biotech AG plans to pursue legal action against Unither over assets related to Carragelose and Marinosolv. The report does not specify the nature of the legal options or the assets involved.Global Market Insights Inc.Blow-Fill-Seal Packaging Market Size, Forecasts Report 2035The global blow-fill-seal (BFS) packaging market was valued at USD 3.8 billion in 2025 and is projected to reach USD 7.6 billion by 2035, growing at a CAGR of 7.3% during the forecast period, according to a report by Global Market Insights Inc. North America held the largest regional market share at 33.1% in 2025, while Asia Pacific is expected to be the fastest-growing region with a projected CAGR of 9.6%. Key market drivers include increasing demand for sterile pharmaceutical packaging, stringent aseptic manufacturing regulations, growing adoption of single-dose and preservative-free drug delivery systems, and expansion of biologics and vaccine manufacturing. The top five market players—Unither Pharmaceuticals, Fresenius Kabi AG, Recipharm AB, The Ritedose Corporation, and Nephron Pharmaceuticals—collectively held a 21.2% market share in 2025, with recent strategic investments including Unither's EUR 140 million ophthalmology facility expansion in France.Business Wire BlogOra Unveils Breakthrough Research in Ophthalmic Clinical Trials, New Blind Canvas Project Stories at ARVO 2026Ora announced its ARVO 2026 poster presentations on AI-driven image analysis, retinal endpoints, and dry eye treatment efficacy. The company also sponsors Eyecelerator and launches Eye to Market, while updating The Blind Canvas Project with seven storytellers' interviews.PharmafileNew web series explores path from ophthalmic research to patient accessA new YouTube web series, Eye to Market, launched by Eyecelerator with Unither Pharmaceuticals and Ora, Inc, examines how ophthalmic innovations progress from research to patient access. The series covers clinical development, regulatory strategy, manufacturing scale-up, and global access, aiming to make the process more transparent. Episodes will be published on the Eyecelerator YouTube channel.NewswiseEyecelerator Teams up With Unither Pharmaceuticals and Ora for Web Series on Transforming Ophthalmic Innovation into Market-Ready TherapiesEyecelerator announced a collaboration with Unither Pharmaceuticals and Ora, Inc. to launch 'Eye to Market,' a new web series exploring how ophthalmic innovations move from scientific development to real-world patient adoption. The series will feature expert interviews covering topics including translational research, clinical development, manufacturing, regulatory strategy, and market access across the ophthalmology industry. Episodes will be published on the Eyecelerator YouTube channel and shared across partner channels, targeting innovators, clinicians, investors, manufacturers, and industry leaders.EIN PresswireFrance Blow Fill Seal Technology Market Driven by Biologics Demand, Led by Unither Pharmaceuticals, Catalent, RommelagFact.MR released a market analysis projecting the France Blow Fill Seal technology market to grow from approximately USD 230 million in 2026 to USD 480 million by 2036, representing a compound annual growth rate of 7.3%.PharmiWeb.comSeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidateSeaBeLife, a French biotechnology company developing drug candidates to block cellular necrosis, has signed a joint development agreement with Unither Pharmaceuticals, a French pharmaceutical CDMO, to formulate and produce the topical ophthalmic formulation of its SBL03 drug candidate for treating degenerative retinal disorders. The partnership covers pharmaceutical development, industrial scale-up, and GMP batch manufacturing, with the goal of starting Phase 1 clinical trials in 2027 for geographic atrophy and dry age-related macular degeneration. SeaBeLife retains ownership of the drug candidate while Unither handles the pharmaceutical development and manufacture, combining scientific expertise with industrial capabilities.